Wyszuk. zaawans.

Tom 2, Nr 3-4 (2022)
STANOWISKO EKSPERTÓW
Opublikowany online: 2022-09-08

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 484
Wyświetlenia/pobrania artykułu 374
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Rekomendacje profilaktyki infekcji SARS-CoV-2 u chorych immunoniekompetentnych

Krzysztof Tomasiewicz1, Alicja Dębska-Ślizień2, Magdalena Durlik3, Krzysztof Giannopoulos4, Iwona Hus56, Piotr Rutkowski7
Hematologia - Edukacja 2022;2(3-4):103-111.

Streszczenie

Brak

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21(7): 904–913.
    CrossRefPubMed
  2. Yarza R, Bover M, Paredes D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer. 2020; 135: 242–250.
    CrossRefPubMed
  3. Mileham KF, Bruinooge SS, Aggarwal C, et al. Changes over time in COVID-19 severity and mortality in patients undergoing cancer treatment in the United States: initial report from the ASCO Registry. JCO Oncol Pract. 2022; 18(4): e426–e441.
    CrossRefPubMed
  4. Pinato DJ, Tabernero J, Bower M, et al. OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021; 22(12): 1669–1680.
    CrossRefPubMed
  5. Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer. 2020; 141: 92–104.
    CrossRefPubMed
  6. Park R, Lee SA, Kim SY, et al. Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data. Acta Oncol. 2021; 60(1): 13–19.
    CrossRefPubMed
  7. Kuderer NM, Choueiri TK, Shah DP, et al. COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395(10241): 1907–1918.
    CrossRefPubMed
  8. Hitchman L, Machin M. COVIDSurg Collaborative and Vascular and Endovascular Research Network, COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020; 396(10243): 27–38.
    CrossRefPubMed
  9. Zou C, Huang Y, Ma Y, et al. Re: A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19: Clinical outcomes of SARS-CoV-2-infected cancer patients undergoing surgery. Eur J Cancer. 2021; 152: 245–247.
    CrossRefPubMed
  10. Lee LYW, Cazier JB, Starkey T, et al. et al.. UK Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21(10): 1309–1316.
    CrossRefPubMed
  11. Passamonti F, Cattaneo C, Arcaini L, et al. ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020; 7(10): e737–e745.
    CrossRefPubMed
  12. Pagano L, Salmanton-García J, Marchesi F, et al. EPICOVIDEHA working group. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021; 14(1): 168.
    CrossRefPubMed
  13. Chatzikonstantinou T, Kapetanakis A, Scarfò L, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021; 35(12): 3444–3454.
    CrossRefPubMed
  14. Puła B, Pruszczyk K, Pietrusza E, et al. Outcome of SARS-CoV-2-infected Polish patients with chronic lymphocytic leukemia. Cancers (Basel). 2022; 14(3).
    CrossRefPubMed
  15. Breccia M, Abruzzese E, Accurso V, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol. 2022; 196(3): 559–565.
    CrossRefPubMed
  16. Claudiani S. Is COVID-19 less severe in CML patients than in those with other haematological cancers? Br J Haematol. 2022; 196(3): 471–472.
    CrossRefPubMed
  17. García-Suárez J, de la, Cedillo Á, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity a nd mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020; 13(1): 133.
  18. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020; 136(25): 2881–2892.
    CrossRefPubMed
  19. Aries JA, Davies JK, Auer RL, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol. 2020; 190(2): e64–e67.
    CrossRefPubMed
  20. Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020; 105(5): 597–607.
    CrossRefPubMed
  21. Shah V, Ko Ko T, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020; 190(5): e279–e282.
    CrossRefPubMed
  22. Ljungman P, Mikulska M, de la Camara R, et al. European Society for Blood and Marrow Transplantation. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020; 55(11): 2071–2076.
    CrossRefPubMed
  23. Spanjaart AM, Ljungman P, de La Camara R, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021; 35(12): 3585–3588.
    CrossRefPubMed
  24. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008; 3(5): 1526–1533.
    CrossRefPubMed
  25. Green M. Introduction: infections in solid organ transplantation. Am J Transplant. 2013; 13(Suppl 4): 3–8.
    CrossRefPubMed
  26. De Meester J, De Bacquer D, Naesens M, et al. NBVN Kidney Registry Group. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J Am Soc Nephrol. 2021; 32(2): 385–396.
    CrossRefPubMed
  27. Willicombe M, Gleeson S, Clarke C, et al. ICHNT Renal COVID Group. Identification of patient characteristics associated with SARS-CoV-2 infection and outcome in kidney transplant patients using serological screening. Transplantation. 2021; 105(1): 151–157.
    CrossRefPubMed
  28. Kates OS, Haydel BM, Florman SS, et al. UW COVID-19 SOT Study Team. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. 2021; 73(11): e4090–e4099.
    CrossRefPubMed
  29. Cravedi P, Mothi SS, Azzi Y, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020; 20(11): 3140–3148.
    CrossRefPubMed
  30. Chen JJ, Kuo G, Lee TH, et al. Incidence of mortality, acute kidney injury and graft loss in adult kidney transplant recipients with coronavirus disease 2019: systematic review and meta-analysis. J Clin Med. 2021; 10(21).
    CrossRefPubMed
  31. Cristelli MP, Viana LA, Dantas MTC, et al. The full spectrum of COVID-19 development and recovery among kidney transplant recipients. Transplantation. 2021; 105(7): 1433–1444.
    CrossRefPubMed
  32. Mandal A, Singh P, Samaddar A, et al. Vaccination of cancer patients against COVID-19: towards the end of a dilemma. Med Oncol. 2021; 38(8): 92.
    CrossRefPubMed
  33. Romano E, Pascolo S, Ott P. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. J Immunother Cancer. 2021; 9(6).
    CrossRefPubMed
  34. Heudel P, Favier B, Assaad S, et al. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients. Ann Oncol. 2021; 32(11): 1443–1444.
    CrossRefPubMed
  35. Slomski A. Most fully vaccinated patients with cancer have SARS-CoV-2 Antibodies. JAMA. 2021; 326(9): 800.
    CrossRefPubMed
  36. Goshen-Lago T, Waldhorn I, Holland R, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021; 7(10): 1507–1513.
    CrossRefPubMed
  37. Zeng C, Evans JP, Reisinger S, et al. Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. Cell Biosci. 2021; 11(1): 197.
    CrossRefPubMed
  38. Tang K, Wei Z, Wu Xi. Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis. J Med Virol. 2022; 94(10): 4860–4868.
    CrossRefPubMed
  39. Bordry N, Addeo A, Jaksic C, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021; 39(8): 1091–1098.e2.
    CrossRefPubMed
  40. Rizzo A, Palmiotti G. SARS-CoV-2 Omicron variant in cancer patients: an insight into the vaccine booster debate. Future Oncol. 2022; 18(11): 1301–1302.
    CrossRefPubMed
  41. Malard F, Gaugler B, Gozlan J, et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 2021; 11(8): 142.
    CrossRefPubMed
  42. Zaleska J, Kwasnik P, Paziewska M, et al. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients. Int J Cancer. 2022 [Epub ahead of print].
    CrossRefPubMed
  43. Stampfer SD, Goldwater MS, Jew S, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021; 35(12): 3534–3541.
    CrossRefPubMed
  44. Carr EJ, Kronbichler A, Graham-Brown M, et al. Review of early immune response to SARS-CoV-2 vaccination among patients with CKD. Kidney Int Rep. 2021; 6(9): 2292–2304.
    CrossRefPubMed
  45. Tylicki L, Biedunkiewicz B, Dąbrowska M, et al. Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: the COViNEPH Project. Pol Arch Intern Med. 2021; 131(9): 797–801.
    CrossRefPubMed
  46. Dębska-Ślizień A, Ślizień Z, Muchlado M, et al. Predictors of humoral response to mRNA COVID19 vaccines in kidney transplant recipients: a longitudinal study — the COViNEPH Project. Vaccines (Basel). 2021; 9(10).
    CrossRefPubMed
  47. Benotmane I, Gautier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021; 99(6): 1498–1500.
    CrossRefPubMed
  48. Stumpf J, Siepmann T, Lindner T, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021; 9: 100178.
    CrossRefPubMed
  49. Dębska-Ślizień A, Ślizień Z, Muchlado M, et al. Predictors of humoral response to mRNA COVID19 vaccines in kidney transplant recipients: a longitudinal study — the COViNEPH Project. Vaccines (Basel). 2021; 9(10).
    CrossRefPubMed
  50. Naylor KL, Kim SJ, Smith G, et al. Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada. Am J Transplant. 2022; 22(9): 2228–2236.
    CrossRefPubMed
  51. WHO. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines. https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply.
  52. WHO. Interim recommendations for heterologous COVID-19 vaccination schedules. https://www.who.int/news/item/16-12-2021-interim-recommendations-for-heterologous-covid-19-vaccine-schedules.
  53. Grewal R, Kitchen S, Nguyen L, et al. Effectiveness of a fourth dose of COVID-19 vaccine among long-term care residents in Ontario, Canada: test-negative design study. BMJ. 2022; 378: e071502.
    CrossRef
  54. Evusheld ChPL. https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_pl.pdf.
  55. Montgomery H, Hobbs FD, Padilla F, et al. TACKLE study group. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022 [Epub ahead of print].
    CrossRefPubMed
  56. Levin MJ, Ustianowski A, De Wit S, et al. PROVENT Study Group. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022; 386(23): 2188–2200.
    CrossRefPubMed
  57. Al Jurdi A, Morena L, Cote M, et al. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave. Am J Transplant. 2022 [Epub ahead of print].
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna